[e-drug] Therapeutics Letter: Clinical implications of recent trials

["Ciprian Jauca" <jauca@ti.ubc.ca>]

E-DRUG: Therapeutics Letter: Clinical implications of recent trials
-------------------------------------------------------------------

Therapeutics Letter #65 (Jul-Aug 2007): Clinical implications of recent key therapeutic trials: http://ti.ubc.ca/en/node/159

I would like to bring to your attention the latest issue (#65) of the Therapeutics Letter: "Clinical implications of recent key therapeutic trials" that has just been posted on the Therapeutics Initiative web site at:

http://ti.ubc.ca/en/node/159 

Randomized controlled clinical trials (RCTs) are critical in determining the net health effect of a therapy (benefit minus harm). When the primary outcome of the trial is the reduction in one or more serious adverse events, the best measure of the net health effect of the drug is the total number of people with at least one serious adverse event. When the total number of people with at least one serious adverse event is not reported, total mortality is the next best measure of net health effect. In this Letter we use this analytic perspective to interpret the results and clinical implications of four recent RCTs. 

I invite you to drop by and have a look at this Letter. Please feel free to forward this message to any of your friends or colleagues that might be interested in this topic.

We would appreciate receiving your comments on this Therapeutics Letter and its possible implications in clinical practice.

Regards,

Ciprian Jauca
Program Coordinator
Therapeutics Initiative
University of British Columbia
Department of Anesthesiology, Pharmacology & Therapeutics
2176 Health Sciences Mall
Vancouver, BC V6T 1Z3
Canada
Email: jauca@ti.ubc.ca
Tel: +1-604-822-0700
Fax: +1-604-822-0701
Web: www.ti.ubc.ca